Cerus (CERS) CMO sells 125,894 shares, receives 55,220-share grant

Rhea-AI Filing Summary

CERUS CORP’s Chief Medical Officer Benjamin Richard J reported a mix of stock awards and planned sales. On March 5, 2026, he acquired 55,220 shares of common stock as a grant or award at no cost, increasing his direct holdings.

He then reported selling a total of 125,894 common shares in open-market transactions on March 5, 6, and 9, 2026 at weighted average prices of about $2.06, $2.01, and $1.88 per share. Footnotes state these sales were made under a Rule 10b5-1 trading plan and instructions elected on the grant date to cover statutory tax withholding and related fees, and are described as non-discretionary. After these transactions, he directly owns 879,101 Cerus common shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Benjamin Richard J

(Last) (First) (Middle)

C/O CERUS CORPORATION

1220 CONCORD AVE SUITE 600

(Street)

CONCORD CA 94520

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CERUS CORP [ CERS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)
03/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/05/2026		A		55,220	A	$0.00	1,004,995	D
Common Stock	03/05/2026		S		61,233(1)	D	$2.0626(2)	943,762	D
Common Stock	03/06/2026		S		24,235(3)	D	$2.0055(4)	919,527	D
Common Stock	03/09/2026		S		40,426(1)	D	$1.8807(5)	879,101	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares sold pursuant to a 10b5-1 plan and does not represent a discretionary sale by the reporting person.

2. Represents a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $2.02 to $2.17 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the aforementioned range set forth.

3. Represents shares sold pursuant to an instruction intended to comply with the requirement of Rule 10b5-1 that was elected by the Reporting Person on the date of grant to cover statutory tax withholding obligations and corresponding brokerage fees in connection with the vesting of certain restricted stock units and does not represent a discretionary sale by the reporting person.

4. Represents a weighted average sales price. These shares were sold in a block trade per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold pursuant to such block trade.

5. Represents a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $1.855 to $1.91 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the aforementioned range set forth.

	Richard J. Benjamin, by Chrystal N. Jensen, attorney-in-fact	03/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Cerus (CERS) report for its CMO in this Form 4/A?

Cerus reported that Chief Medical Officer Benjamin Richard J received a grant of 55,220 common shares on March 5, 2026, then sold 125,894 shares in open-market transactions on March 5, 6, and 9, 2026, under pre-arranged instructions.

Were the Cerus (CERS) CMO stock sales discretionary?

The filing states the Cerus CMO’s sales were not discretionary. Shares were sold under a Rule 10b5-1 trading plan and instructions elected on the grant date to cover statutory tax withholding obligations and related brokerage fees linked to vesting restricted stock units.

How many Cerus (CERS) shares does the CMO hold after these transactions?

Following the reported March 9, 2026 transaction, the Cerus Chief Medical Officer directly owns 879,101 shares of Cerus common stock. This figure reflects the net result of the 55,220-share grant and subsequent sales totaling 125,894 shares reported in the Form 4/A.

At what prices were Cerus (CERS) shares sold in this Form 4/A?

Reported weighted average sale prices were about $2.0626, $2.0055, and $1.8807 per share. Footnotes explain some trades occurred in ranges from $2.02–$2.17 and $1.855–$1.91 per share, with full breakdowns available on request to the company or regulators.

What type of stock award did the Cerus (CERS) CMO receive?

On March 5, 2026, the Cerus Chief Medical Officer acquired 55,220 common shares at a reported price of $0.00 per share. The transaction is described as a grant, award, or other acquisition, linked in the footnotes to the vesting of restricted stock units.

What does the Rule 10b5-1 plan reference mean in the Cerus (CERS) filing?

The filing explains that certain Cerus CMO sales were made under an instruction intended to comply with Rule 10b5-1, elected on the grant date. This indicates pre-set trading arrangements and tax-withholding instructions rather than opportunistic or discretionary timing by the reporting executive.